DE3854125T3 - VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN. - Google Patents

VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.

Info

Publication number
DE3854125T3
DE3854125T3 DE3854125T DE3854125T DE3854125T3 DE 3854125 T3 DE3854125 T3 DE 3854125T3 DE 3854125 T DE3854125 T DE 3854125T DE 3854125 T DE3854125 T DE 3854125T DE 3854125 T3 DE3854125 T3 DE 3854125T3
Authority
DE
Germany
Prior art keywords
improved method
factor viii
type proteins
producing factor
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3854125T
Other languages
English (en)
Other versions
DE3854125T2 (de
DE3854125D1 (de
Inventor
Randal Kaufman
S Adamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26711519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3854125(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE3854125D1 publication Critical patent/DE3854125D1/de
Publication of DE3854125T2 publication Critical patent/DE3854125T2/de
Application granted granted Critical
Publication of DE3854125T3 publication Critical patent/DE3854125T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE3854125T 1987-04-06 1988-04-06 VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN. Expired - Lifetime DE3854125T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3488287A 1987-04-06 1987-04-06
US6886587A 1987-07-02 1987-07-02
PCT/US1988/001114 WO1988008035A1 (en) 1987-04-06 1988-04-06 IMPROVED METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS

Publications (3)

Publication Number Publication Date
DE3854125D1 DE3854125D1 (de) 1995-08-10
DE3854125T2 DE3854125T2 (de) 1996-01-04
DE3854125T3 true DE3854125T3 (de) 2000-10-12

Family

ID=26711519

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854125T Expired - Lifetime DE3854125T3 (de) 1987-04-06 1988-04-06 VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.

Country Status (6)

Country Link
EP (1) EP0362218B2 (de)
JP (1) JPH02503744A (de)
AT (1) ATE124725T1 (de)
CA (1) CA1331157C (de)
DE (1) DE3854125T3 (de)
WO (1) WO1988008035A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
US7247475B2 (en) 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
AU6486196A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
EP1062244B1 (de) 1998-03-12 2002-08-28 Genetics Institute, LLC Verbessertes verfahren zur herstellung von faktor viii
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
ES2541470T3 (es) 1999-02-22 2015-07-20 University Of Connecticut Formulaciones de factor VIII libres de albúmina
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
EP1988101A1 (de) 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
ME02964B (de) 2009-12-06 2018-07-20 Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zu ihrer anwendung
EP2591101B1 (de) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
ES2556454T3 (es) 2010-10-05 2016-01-18 Novo Nordisk Health Care Ag Proceso para producción de proteínas
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
PL2729161T3 (pl) 2011-07-08 2019-08-30 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CA2863328A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
HUE041595T2 (hu) 2012-01-12 2019-05-28 Bioverativ Therapeutics Inc A VIII-as faktorral szembeni immunogenitás csökkentése a VIII-as faktorterápiát kapó egyéneknél
EP4194465A1 (de) 2012-02-15 2023-06-14 Bioverativ Therapeutics Inc. Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
TWI629993B (zh) 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
CN105392495A (zh) 2013-06-28 2016-03-09 比奥根Ma公司 具有xten的凝血酶可裂解连接子和其用途
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
EP3033097B1 (de) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Faktor viii-xten fusionen sowie ihre verwendungen.
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813389A (ja) * 1981-07-16 1983-01-25 Kyowa Hakko Kogyo Co Ltd 細胞培養用培地
JPS5823784A (ja) * 1981-08-04 1983-02-12 Ajinomoto Co Inc 哺乳動物細胞用培地
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
DE3785102T2 (de) * 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
AU606925B2 (en) * 1987-01-30 1991-02-21 Biogen, Inc. A method for producing factor viii in high yield

Also Published As

Publication number Publication date
EP0362218B2 (de) 2000-04-12
JPH02503744A (ja) 1990-11-08
EP0362218A1 (de) 1990-04-11
DE3854125T2 (de) 1996-01-04
CA1331157C (en) 1994-08-02
ATE124725T1 (de) 1995-07-15
DE3854125D1 (de) 1995-08-10
WO1988008035A1 (en) 1988-10-20
EP0362218A4 (en) 1990-09-19
EP0362218B1 (de) 1995-07-05

Similar Documents

Publication Publication Date Title
ATE124725T1 (de) Verbessertes verfahren zur herstellung von faktor viii:c-typ-proteinen.
DE3785102T2 (de) Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
ATE247708T1 (de) Verfahren zur regulierung der metabolischen stabilität von proteinen
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE69637867D1 (de) Verfahren zur Kontrollierung der Sialylierung von durch Säugetierzellkultur hergestellten Proteinen
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
ATE258189T1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
FI852547L (fi) Framstaellning av faktor viii och daertill hoerande produkter.
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE3862306D1 (de) Verfahren zur elektrochemischen herstellung von carbonsaeuren.
DE69430975T2 (de) Verfahren zur Herstellung von Proteinen
DE3886292D1 (de) Expressionsvektoren und Verfahren unter deren Verwendung zur Gewinnung von Cro/beta-Galaktosidase/PTH-Fusionsproteinen und von PTH.
DE69425809D1 (de) Methoden zur Herstellung von Protein C
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
AT387906B (de) Verfahren zur herstellung von biologisch vertraeglichen materialien
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE3678552D1 (de) Verfahren zur herstellung von proteinen unter verwendung von transformierten milchsaeurebakterien.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.
DE3677421D1 (de) Mikrobiologisches verfahren zur herstellung von menschlichem lysozym.
DE3782350D1 (de) Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung.
DE3574967D1 (de) Verfahren zur herstellung von 3-(4-fluorphenoxy)-propionitril und verfahren zur herstellung von 6-fluor-4-chromanon unter verwendung von 3-(4-fluorphenoxy)-propionitril.
ATE110775T1 (de) Verfahren zur herstellung von hirudin.
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
ATE71145T1 (de) Expressionsvektoren, solche vektoren enthaltende wirtszellen und verfahren zur herstellung gewuenschter produkte unter verwendung solcher zellen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US